UK re­lies on EMA's re­view of Xge­va re­for­mu­la­tion in first-ever rec­i­p­ro­cal ap­proval

For the first time since Brex­it, the UK’s med­i­cines reg­u­la­tor has made use of its new ap­proval path­way that can speed drug ap­provals based on the work of reg­u­la­tors in oth­er coun­tries.

In this case, the UK’s MHRA is re­ly­ing on the work of the Eu­ro­pean Med­i­cines Agency to sign off on a new for­mu­la­tion for Am­gen’s bone drug Xge­va (deno­sum­ab) in just 30 days. No new clin­i­cal tri­als were nec­es­sary for the for­mu­la­tion change.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER